Статьи и публикации

Случай диагностики болезни Андерсона-Фабри
Случай болезни Фабри у взрослого глазами кардиолога и генетика
Поражение сердца при болезни Фабри: как заподозрить, диагностировать и лечить?

Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005;65:600-2

Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry's disease. A histochemical and electron microscopic study. Am J Cardiol 1969;24:95-110

Fischer E. [Fabry disease, a disease with rheumatic aspects: radiology of soft tissue and bone changes in the hand]. Z Rheumatol 1986;45:36-41

Font RL, Fine BS. Ocular pathology in Fabry's disease. Histochemical and electron microscopic observations. Am J Ophthalmol 1972;73:419-30

Francois J, De Becker L. [The ocular manifestations of chloroquine intoxication]. Ann Ocul (Paris) 1965; 198:513-44

Friedman LS, Kirkham SE, Thistlethwaite JR, Platika D, Kolodny EH, Schuffler MD. Jejunal diverticulosis with perforation as a complication of Fabry's disease. Gastroenterology 1984;86:558-63

Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an a-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 2003;80:307-14

Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32

Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry's disease.J Med Genet 1983;20:309-12

Gal A, Schafer E, Rohard I. The genetic basis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis Ltd; 2006: p. 323-30

Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human a-galactosidase. J Mol Biol 2004;337:319-35

Gehler J, Sewell AC, Becker C, Hartmann J, Spranger J. Clinical and biochemical delineation of aspartyl- glycosaminuria as observed in two members of an Italian family. Helv Paediatr Acta 1981;36:179-89

Gemignani F, Marbini A, Bragaglia MM, Govoni E. Pathological study of the sural nerve in Fabry's disease. Eur Neurol 1984;23:173-81

Germain DP. Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs 2002; 11:1467-76

Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002;3:10

Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet2005;68:93-5

Germain D, Biasotto M, Tosi M, Meo T, Kahn A, Poenaru L. Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the a-galactosidase A gene and detection of carriers in Fabry disease. Hum Genet 1996;98:719-26

Ginsberg L, Manara R, Valentine AR, Kendall B, Burlina AP. Magnetic resonance imaging changes in Fabry disease. Acta Paediatr 2006;95 (Suppl 451):57-62

Ginsberg L, Valentine A, Mehta A. Neurological rarity – Fabry disease. Practical Neurology 2005;5:110-13

Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-27

Gordon KE, Ludman MD, Finley GA. Successful treatment ofpainful crises of Fabry disease with low dose morphine. Pediatr Neurol 1995;12:250-1

Grabenhorst E, Schlenke P, Pohl S, Nimtz M, Conradt HS. Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells. Glycoconj J 1999;16:81-97

Grewal RP. Psychiatric disorders in patients with Fabry's disease. Int J Psychiatry Med 1993;23:307-12